|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 1992; 20:1452-1459 © 1992 by the American College of Cardiology Foundation |
Department of Medicine, University of Washington School of Medicine, Seattle.
OBJECTIVES. The aim of this study was to determine whether streptokinase treatment improves long-term survival in patients with acute myocardial infarction. BACKGROUND. Thrombolytic treatment for acute myocardial infarction reduces early mortality and improves the 1-year survival rate, but the long-term (3 to 8 years) survival benefits of treatment and the relation between survival and baseline clinical characteristics, infarct size and ventricular function have not been established. METHODS. We assessed survival status at a minimum of 3 and a mean of 4.9 +/- 2.3 years in 618 patients randomized between 1981 and 1986 to receive conventional treatment (n = 293) or thrombolysis with streptokinase (n = 325) in the Western Washington Intracoronary (n = 250) and Intravenous (n = 368) Streptokinase in Myocardial Infarction trials. The relation between long-term survival and thrombolytic treatment, admission baseline clinical characteristics and late radionuclide tomographic thallium-201 infarct size and ejection fraction was assessed in a subset of patients. RESULTS. Survival at 6 weeks was 94% in patients who received streptokinase versus 88% in the control group (p = 0.01). However, survival at 3 years was 84% in the streptokinase group and 82% in the control group and for the total period of follow-up, there was no significant survival benefit (p = 0.16). Analysis by infarct location showed a higher survival rate at 3 years for patients treated with anterior infarction (76% vs. 67% for the control group), but no overall survival benefit (p = 0.14). Survival at 3 years for patients with an inferior infarction was 89% in the streptokinase group and 91% in the control group (p = 0.62). By stepwise Cox regression analysis, admission clinical variables associated with decreased long-term survival were anterior infarction, advanced age, history of prior infarction and the presence of pulmonary edema or hypotension. Although streptokinase therapy was associated with improved survival, it was not an independent determinant of survival (p = 0.069). Ejection fraction and thallium-201 infarct size measured approximately 8 weeks after enrollment had a strong association with long-term survival. Univariate analysis in a subgroup of 289 patients with complete data selected infarct size, ejection fraction, age and history of prior infarction as predictors of survival. In the multivariate model, only ejection fraction (p < 0.0001), age (p = 0.008) and prior myocardial infarction (p = 0.02) remained strong predictors. CONCLUSIONS: In these early trials of thrombolytic therapy for acute myocardial infarction, streptokinase improved early survival, but there was little long-term survival benefit. This failure to show an improvement in the 3- to 8-year survival rate may also reflect the need to study a larger group of patients or to initiate treatment earlier after symptom onset.
This article has been cited by other articles:
|
|
 |
|
  S. R. Dixon, R. J. Whitbourn, M. W. Dae, E. Grube, W. Sherman, G. L. Schaer, J. S. Jenkins, D. S. Baim, R. J. Gibbons, R. E. Kuntz, et al. Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction J. Am. Coll. Cardiol., December 4, 2002; 40(11): 1928 - 1934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Kennedy Thrombolytic therapy in acute myocardial infarction J. Am. Coll. Cardiol., April 1, 2000; 35(5_Suppl_B): 25B - 28B. [PDF]
|
|
|
|
 |
|
 R. J. Gibbons, T. D. Miller, and T. F. Christian Infarct Size Measured by Single Photon Emission Computed Tomographic Imaging With 99mTc-Sestamibi : A Measure of the Efficacy of Therapy in Acute Myocardial Infarction Circulation, January 4, 2000; 101(1): 101 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Buxton, K. L. Lee, J. D. Fisher, M. E. Josephson, E. N. Prystowsky, G. Hafley, and The Multicenter Unsustained Tachycardia Trial Inve A Randomized Study of the Prevention of Sudden Death in Patients with Coronary Artery Disease N. Engl. J. Med., December 16, 1999; 341(25): 1882 - 1890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. French, T. A. Hyde, H. Patel, D. J. Amos, S. C. McLaughlin, B. J. Webber, and H. D. White Survival 12 years after randomization to streptokinase: the influence of thrombolysis in myocardial infarction flow at three to four weeks J. Am. Coll. Cardiol., July 1, 1999; 34(1): 62 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Kennedy Thrombolytic therapy in acute myocardial infarction J. Am. Coll. Cardiol., June 1, 1999; 33(7): 1829 - 1832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Franzosi, E. Santoro, C. De Vita, E. Geraci, A. Lotto, A. P. Maggioni, F. Mauri, F. Rovelli, L. Santoro, L. Tavazzi, et al. Ten-Year Follow-Up of the First Megatrial Testing Thrombolytic Therapy in Patients With Acute Myocardial Infarction : Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 Study Circulation, December 15, 1998; 98(24): 2659 - 2665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Baigent, R. Collins, P. Appleby, S. Parish, P. Sleight, and R. Peto ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither BMJ, May 2, 1998; 316(7141): 1337 - 1343. [Abstract] [Full Text]
|
|
|
|
|
|
H. D. White and F. J. J. Van de Werf Thrombolysis for Acute Myocardial Infarction Circulation, April 28, 1998; 97(16): 1632 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Dakik, J. J. Mahmarian, K. T. Kimball, M. G. Koutelou, R. Medrano, and M. S. Verani Prognostic Value of Exercise 201Tl Tomography in Patients Treated With Thrombolytic Therapy During Acute Myocardial Infarction Circulation, December 1, 1996; 94(11): 2735 - 2742. [Abstract] [Full Text]
|
|
|
|
|
|
H. D. White, G. I. Barbash, R. M. Califf, R. J. Simes, C. B. Granger, W. D. Weaver, N. S. Kleiman, P. E. Aylward, J. M. Gore, A. Vahanian, et al. Age and Outcome With Contemporary Thrombolytic Therapy: Results From the GUSTO-I Trial Circulation, October 15, 1996; 94(8): 1826 - 1833. [Abstract] [Full Text]
|
|
|
|
|
|
M. H. Raitt, C. Maynard, G. S. Wagner, M. D. Cerqueira, R. H. Selvester, and W. D. Weaver Relation Between Symptom Duration Before Thrombolytic Therapy and Final Myocardial Infarct Size Circulation, January 1, 1996; 93(1): 48 - 53. [Abstract] [Full Text]
|
|
|
|
|
|
T. D. Miller, T. F. Christian, M. R. Hopfenspirger, D. O. Hodge, B. J. Gersh, and R. J. Gibbons Infarct Size After Acute Myocardial Infarction Measured by Quantitative Tomographic 99mTc Sestamibi Imaging Predicts Subsequent Mortality Circulation, August 1, 1995; 92(3): 334 - 341. [Abstract] [Full Text]
|
|
|
|
|
|
D. B. Mark, M. A. Hlatky, R. M. Califf, C. D. Naylor, K. L. Lee, P. W. Armstrong, G. Barbash, H. White, M. L. Simoons, C. L. Nelson, et al. Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial Infarction N. Engl. J. Med., May 25, 1995; 332(21): 1418 - 1424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 DOES THROMBOLYTIC THERAPY FOR MI PROLONG SURVIVAL Journal Watch (General), December 25, 1992; 1992(1225): 2 - 2. [Full Text]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
